Â鶹ÊÓƵ

Paul, Weiss advised PCI Pharma and its existing lead investor, Kohlberg, on PCI’s receipt of a strategic investment co-led by Kohlberg and Bain Capital, and supported by significant reinvestment from Mubadala Investment Company. PCI is a leading global contract development and manufacturing organization focused on innovative biotherapies. Partners Group will continue to support PCI with a minority investment. Financial terms of the transaction were not disclosed.

Kohlberg, Mubadala and Bain, in partnership with PCI’s management team, intend to accelerate PCI’s growth, build upon its strong customer service experience and further enable its clients to bring life-changing biopharmaceutical therapies to market. PCI will primarily focus on organic and inorganic growth initiatives, such as expanding its suite of services and geographic reach—including its significant continued investment in the U.S.

The Paul, Weiss team was led by corporate partners Angelo Bonvino, Samuel Welt and Lukas Richards, and included partners Oliver Marcuse, Thomas de la Bastide, Suhan Shim, Matthew Goldstein and Andrew Day and counsel Robert Balis and Nathan Mitchell; tax partner Lindsay Parks and counsel Christina Cerrito and Jamie Chambers; antitrust partners Annie Herdman and Marta Kelly and counsel Chad de Souza; intellectual property partner Bonnie Chen; executive compensation partner Ron Aizen; environmental counsel William O’Brien; and litigation counsel Audrey Paquet.